Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma

NCT04054518 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Durvalumab

Sponsor

Tiago Biachi